在大型学术-社区联合实践中实施精准医学胸部服务:基于院内反射检测
该研究描述了在学术-社区联合实践中实施的IV期非小细胞肺癌精准医学服务(PREDICT),包括院内反射检测、护士导航、分子肿瘤委员会和信息门户。实施后NGS检测率从60.8%升至91.3%,NGS和PD-L1的周转时间显著缩短,可操作基因组改变检出率从22%升至29.3%,靶向治疗使用率从6.8%升至10.6%。决策分析模型预测该策略可改善生存。
要点
- PREDICT服务使IV期NSCLC的NGS检测率从60.8%提高至91.3%。
- NGS周转时间从18天缩短至12天,PD-L1从10天缩短至7天。
- 可操作基因组改变检出率从22%提高至29.3%,靶向治疗使用率从6.8%升至10.6%。
核心结论
- 在学术-社区联合实践中实施包含反射检测、护士导航、分子肿瘤委员会和信息门户的精准医学服务,可提高NGS检测率、缩短周转时间、增加可操作突变检出和一线靶向治疗使用。
- 决策分析模型预测该策略在所有患者中均具有生存优势。
研究设计与样本
- 研究描述了PREDICT服务的实施,并采用决策分析模型比较四种策略:PREDICT vs 标准治疗(外送测序和PD-L1检测),以及所有IV期NSCLC患者测序 vs 仅非鳞癌组织学患者测序。
- 回顾性纳入2016年1月至2018年12月共626例符合条件的IV期NSCLC患者,PREDICT启动后17个月前瞻性识别290例患者。
主要发现
- PREDICT实施后NGS检测率显著增加(91.3% vs 60.8%;P < .0001)。
- 自活检日起的周转时间显著缩短:NGS为12天 vs 18天(P < .0001),PD-L1为7天 vs 10天(P < .0001)。
- 前瞻性患者中可操作基因组改变检出率为29.3%,回顾性队列为22%(P = .0172)。
- 靶向治疗使用率从6.8%增加至10.6%(P = .048)。
- 决策分析模型预测PREDICT策略在所有患者中生存最优,可操作基因组改变识别率最高,一线化疗使用率最低。
临床怎么用
- 对于IV期NSCLC患者,可考虑实施院内反射NGS和PD-L1检测,并配合护士导航、分子肿瘤委员会和信息门户,以提高检测率和缩短周转时间。
- 该服务模式可能增加可操作突变检出和一线靶向治疗使用,决策分析模型支持其生存优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Broad genomic testing is necessary to treat patients with stage IV non-small cell lung cancer (NSCLC). This article describes a NSCLC precision medicine service at an academic-community practice and provides model-based estimates of the impact of a similar intervention. RESEARCH QUESTION: Will implementation of a precision medicine service increase NSCLC next-generation sequencing (NGS) rates, improve testing turnaround times (TATs), and increase rates of actionable genomic alterations (AGAs)? STUDY DESIGN AND METHODS: The Precision Medicine Thoracic (PREDICT) service consists of: (1) system-wide reflex testing of patients with stage IV NSCLC by in-house solid tumor NGS-focused assay and programmed cell death ligand 1 (PD-L1) testing; (2) nurse navigator oversight; (3) the molecular tumor board; and (4) an integrated information portal (OncoTracker) for real-time updates on sample processing, results, and treatment recommendations by the molecular tumor board. A decision analytic model compared 4 strategies: PREDICT vs standard care (send-out sequencing and PD-L1 testing), and sequencing of all patients with stage IV NSCLC vs patients with non-squamous histology findings only. RESULTS: From January 2016 to December 2018, a total of 626 retrospective patients with stage IV NSCLC were eligible. In the 17 months following the launch of PREDICT, 290 prospective patients were identified. NGS testing rates increased significantly (91.3% vs 60.8%; P < .0001) after PREDICT, whereas TATs from biopsy date were significantly shorter for both NGS (12 vs 18 days; P < .0001) and PD-L1 (7 vs 10 days; P < .0001). AGAs were identified in 29.3% of prospective patients vs 22% of the retrospective cohort (P = .0172). Targeted therapy use increased from 6.8% to 10.6% (P = .048). The decision analytic model predicted superior survival with the PREDICT initiative across all patients, resulting in the highest rates of AGA identification and lowest chemotherapy utilization rates in the first-line setting. INTERPRETATION: Implementation of a precision medicine service for stage IV NSCLC comprising reflex testing, nurse navigation, a molecular tumor board, and an information portal at a combined academic-community practice led to higher NGS testing rates and shorter TATs. The result was identification of more actionable mutations and higher rates of first-line targeted therapy utilization. Decision analytic modeling suggests the superiority of this initiative across all patients.
引用
- Bruno DS, Mirsky MM, Donner AL, et al. Implementing a Precision Medicine Thoracic Service Using In-House Reflex Testing in a Large Academic-Community Practice. Chest. 2025. PMID: 40912295. doi:10.1016/j.chest.2025.07.4095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。